Solid Biosciences (SLDB) Cash from Operations (QoQ) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.81% |
| Dec 31, 2025 | -60.00% |
| Sep 30, 2025 | 10.53% |
| Jun 30, 2025 | -17.46% |
| Mar 31, 2025 | -7.44% |
| Dec 31, 2024 | -25.04% |
| Sep 30, 2024 | -10.44% |
| Jun 30, 2024 | 14.79% |
| Mar 31, 2024 | -20.98% |
| Dec 31, 2023 | -16.35% |
| Sep 30, 2023 | 34.84% |
| Jun 30, 2023 | 1.89% |
| Mar 31, 2023 | 18.81% |
| Dec 31, 2022 | -68.78% |
| Sep 30, 2022 | -28.66% |
| Jun 30, 2022 | 41.60% |
| Mar 31, 2022 | -30.26% |
| Dec 31, 2021 | -13.30% |
| Sep 30, 2021 | -7.74% |
| Jun 30, 2021 | 19.97% |
| Mar 31, 2021 | -1,734.74% |
| Dec 31, 2020 | 108.40% |
| Sep 30, 2020 | -19.10% |
| Jun 30, 2020 | 55.36% |
| Mar 31, 2020 | -37.79% |
| Dec 31, 2019 | -10.42% |
| Sep 30, 2019 | 26.84% |
| Jun 30, 2019 | -1.44% |
| Mar 31, 2019 | -21.13% |
| Dec 31, 2018 | -39.99% |
| Sep 30, 2018 | 6.37% |
| Jun 30, 2018 | 4.90% |
| Mar 31, 2018 | -22.82% |
| Dec 31, 2017 | -48.13% |
| Sep 30, 2017 | 1.75% |
| Jun 30, 2017 | 5.78% |